A comparison of the effects of oral cetirizine and inhaled beclomethasone on early and late asthmatic responses to allergen and the associated increase in airways hyperresponsivenessCitation formats

  • Authors:
  • A M Bentley
  • Samantha Walker
  • F Hanotte
  • C De Vos
  • S R Durham

Standard

A comparison of the effects of oral cetirizine and inhaled beclomethasone on early and late asthmatic responses to allergen and the associated increase in airways hyperresponsiveness. / Bentley, A M; Walker, Samantha; Hanotte, F; De Vos, C; Durham, S R.

In: Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, Vol. 26, No. 8, 08.1996, p. 909-17.

Research output: Contribution to journalArticle

Harvard

Bentley, AM, Walker, S, Hanotte, F, De Vos, C & Durham, SR 1996, 'A comparison of the effects of oral cetirizine and inhaled beclomethasone on early and late asthmatic responses to allergen and the associated increase in airways hyperresponsiveness', Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, vol. 26, no. 8, pp. 909-17.

APA

Bentley, A. M., Walker, S., Hanotte, F., De Vos, C., & Durham, S. R. (1996). A comparison of the effects of oral cetirizine and inhaled beclomethasone on early and late asthmatic responses to allergen and the associated increase in airways hyperresponsiveness. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 26(8), 909-17.

Vancouver

Bentley AM, Walker S, Hanotte F, De Vos C, Durham SR. A comparison of the effects of oral cetirizine and inhaled beclomethasone on early and late asthmatic responses to allergen and the associated increase in airways hyperresponsiveness. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology. 1996 Aug;26(8):909-17.

Author

Bentley, A M ; Walker, Samantha ; Hanotte, F ; De Vos, C ; Durham, S R. / A comparison of the effects of oral cetirizine and inhaled beclomethasone on early and late asthmatic responses to allergen and the associated increase in airways hyperresponsiveness. In: Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology. 1996 ; Vol. 26, No. 8. pp. 909-17.

Bibtex

@article{712220080c4f44e38be7832b9e4fccac,
title = "A comparison of the effects of oral cetirizine and inhaled beclomethasone on early and late asthmatic responses to allergen and the associated increase in airways hyperresponsiveness",
abstract = "BACKGROUND: Cetirizine is a non-sedating H1 antihistamine which is effective in the treatment of allergic rhinitis and urticaria. It inhibits eosinophil and basophil chemotaxis in late cutaneous allergic reactions in skin windows. Its effect on early (EAR) and late asthmatic reactions (LAR) is less certain.METHODS: We examined the effect on EAR and LAR of 3 days treatment with oral cetirizine (15 mg twice daily) compared with a single dose of inhaled beclomethasone 10 min prior to allergen challenge in a placebo-controlled (oral and inhaled) double-blind cross-over design with three treatment arms separated by 14 days.RESULTS: Cetirizine did not significantly inhibit either the EAR or LAR documented by maximum percentage fall in FEV1 (0-3 and 6-9 h) or as area under the curve (AUC between 0 and 3 and 6-9 h). Beclomethasone inhibited the LAR compared with placebo (P = 0.02) when expressed as AUC (6-9 h). This did not quite reach statistical significance (P = 0.06) when expressed as maximal percentage late fall in FEV1 between 6 and 9 h. A greater than twofold increase in airways responsiveness to methacholine was observed 3 h after challenge which was significantly reduced by beclomethasone compared with placebo (P < 0.02) and cetirizine (P < 0.05). The data suggest that oral cetirizine does not significantly inhibit either the EAR or LAR. Beclomethasone inhibited both the early increase in airways responsiveness and the subsequent LAR. Our study also confirms the view that early increases in airway responsiveness precede the late response and suggests that these associated events are not dissociable by the pharmacological treatments employed in this study.",
keywords = "Administration, Inhalation, Administration, Oral, Adult, Allergens/immunology, Antigens, Dermatophagoides, Asthma/drug therapy, Beclomethasone/administration & dosage, Bronchial Hyperreactivity/chemically induced, Cetirizine/administration & dosage, Cross-Over Studies, Double-Blind Method, Female, Forced Expiratory Volume/drug effects, Glycoproteins/immunology, Humans, Hypersensitivity, Immediate/immunology, Male, Middle Aged, Poaceae/immunology, Time Factors",
author = "Bentley, {A M} and Samantha Walker and F Hanotte and {De Vos}, C and Durham, {S R}",
year = "1996",
month = "8",
language = "English",
volume = "26",
pages = "909--17",
journal = "Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology",
issn = "0954-7894",
publisher = "John Wiley & Sons Ltd",
number = "8",

}

RIS

TY - JOUR

T1 - A comparison of the effects of oral cetirizine and inhaled beclomethasone on early and late asthmatic responses to allergen and the associated increase in airways hyperresponsiveness

AU - Bentley, A M

AU - Walker, Samantha

AU - Hanotte, F

AU - De Vos, C

AU - Durham, S R

PY - 1996/8

Y1 - 1996/8

N2 - BACKGROUND: Cetirizine is a non-sedating H1 antihistamine which is effective in the treatment of allergic rhinitis and urticaria. It inhibits eosinophil and basophil chemotaxis in late cutaneous allergic reactions in skin windows. Its effect on early (EAR) and late asthmatic reactions (LAR) is less certain.METHODS: We examined the effect on EAR and LAR of 3 days treatment with oral cetirizine (15 mg twice daily) compared with a single dose of inhaled beclomethasone 10 min prior to allergen challenge in a placebo-controlled (oral and inhaled) double-blind cross-over design with three treatment arms separated by 14 days.RESULTS: Cetirizine did not significantly inhibit either the EAR or LAR documented by maximum percentage fall in FEV1 (0-3 and 6-9 h) or as area under the curve (AUC between 0 and 3 and 6-9 h). Beclomethasone inhibited the LAR compared with placebo (P = 0.02) when expressed as AUC (6-9 h). This did not quite reach statistical significance (P = 0.06) when expressed as maximal percentage late fall in FEV1 between 6 and 9 h. A greater than twofold increase in airways responsiveness to methacholine was observed 3 h after challenge which was significantly reduced by beclomethasone compared with placebo (P < 0.02) and cetirizine (P < 0.05). The data suggest that oral cetirizine does not significantly inhibit either the EAR or LAR. Beclomethasone inhibited both the early increase in airways responsiveness and the subsequent LAR. Our study also confirms the view that early increases in airway responsiveness precede the late response and suggests that these associated events are not dissociable by the pharmacological treatments employed in this study.

AB - BACKGROUND: Cetirizine is a non-sedating H1 antihistamine which is effective in the treatment of allergic rhinitis and urticaria. It inhibits eosinophil and basophil chemotaxis in late cutaneous allergic reactions in skin windows. Its effect on early (EAR) and late asthmatic reactions (LAR) is less certain.METHODS: We examined the effect on EAR and LAR of 3 days treatment with oral cetirizine (15 mg twice daily) compared with a single dose of inhaled beclomethasone 10 min prior to allergen challenge in a placebo-controlled (oral and inhaled) double-blind cross-over design with three treatment arms separated by 14 days.RESULTS: Cetirizine did not significantly inhibit either the EAR or LAR documented by maximum percentage fall in FEV1 (0-3 and 6-9 h) or as area under the curve (AUC between 0 and 3 and 6-9 h). Beclomethasone inhibited the LAR compared with placebo (P = 0.02) when expressed as AUC (6-9 h). This did not quite reach statistical significance (P = 0.06) when expressed as maximal percentage late fall in FEV1 between 6 and 9 h. A greater than twofold increase in airways responsiveness to methacholine was observed 3 h after challenge which was significantly reduced by beclomethasone compared with placebo (P < 0.02) and cetirizine (P < 0.05). The data suggest that oral cetirizine does not significantly inhibit either the EAR or LAR. Beclomethasone inhibited both the early increase in airways responsiveness and the subsequent LAR. Our study also confirms the view that early increases in airway responsiveness precede the late response and suggests that these associated events are not dissociable by the pharmacological treatments employed in this study.

KW - Administration, Inhalation

KW - Administration, Oral

KW - Adult

KW - Allergens/immunology

KW - Antigens, Dermatophagoides

KW - Asthma/drug therapy

KW - Beclomethasone/administration & dosage

KW - Bronchial Hyperreactivity/chemically induced

KW - Cetirizine/administration & dosage

KW - Cross-Over Studies

KW - Double-Blind Method

KW - Female

KW - Forced Expiratory Volume/drug effects

KW - Glycoproteins/immunology

KW - Humans

KW - Hypersensitivity, Immediate/immunology

KW - Male

KW - Middle Aged

KW - Poaceae/immunology

KW - Time Factors

M3 - Article

VL - 26

SP - 909

EP - 917

JO - Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology

JF - Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology

SN - 0954-7894

IS - 8

ER -